The prevalence of Diabetes Mellitus has reached epidemic proportions world-wide and is predicted to increase rapidly in the years to come, putting a tremendous strain on health care budgets in both developed and developing countries. There are two major forms of diabetes and both are associated with decreased beta-cell mass. No treatments have been devised that increase beta-cell mass in vivo in humans, and transplantation of beta-cells is extremely limited due to lack of appropriate donors. For these reasons, increasing functional beta-cell mass in vitro, or in vivo prior to or after transplantatio, has become a "Holy Grail" of diabetes research. Our previous studies clearly show that adult human beta-cells can be induced to replicate, and - importantly - that cells can maintain normal glucose responsiveness after cell division. However, the replication rate achieved was still low, likely due in part to the known age-related decline in the ability of the beta-cell to replicate. W propose to build on our previous findings and to develop more efficacious methods to increase functional beta-cell mass by inducing replication of adult beta-cells, and by restoring juvenile functional properties to aged beta-cells. We will focus on mechanisms derived from studies of non- neoplastic human disease as well as age-related phenotypic changes in human beta-cells.
In Aim 1, we will target the genes altered in patients with marked beta-cell hyperplasia, such as those suffering from Focal Hyperinsulinism of Infancy, Beckwith-Wiedemann Syndrome or Multiple Endocrine Neoplasia. Expression of these genes will be altered in human beta-cells via shRNA-mediated gene suppression and locus-specific epigenetic targeting. Success will be assessed in transplanted human islets by determination of beta-cell replication rate and retention of function.
In Aim 2, we will determine the mechanisms of age-related decline in beta-cell function and replicative capacity, by mapping the changes in the beta-cell epigenome that occur with age. Selected genes will then be targeted as in Aim 1 to improve human beta-cell function, as assessed by glucose responsiveness. To accomplish these aims, we will use cutting-edge and emerging technologies that are already established or are being developed in our laboratories. The research team combines clinical experience with expertise in molecular biology and extensive experience in genomic modification aimed at enhancing beta-cell replication. By basing interventions on changes found in human disease and normal aging, this approach will increase the chances that discoveries made can be translated more rapidly into clinically relevant protocols.
Complications caused by both Type 1 and Type 2 diabetes are a major cause of morbidity and mortality, placing a huge burden on the health systems of both developed and developing nations. The search for a cure is proceeding in many directions, one of which is to develop methods to expand the population of pancreatic beta-cells -- the cells that produce the insulin that maintains blood glucose at a normal level. This has proven exceedingly difficult, since the rate of proliferation of human beta-cells decreases markedly with age. By understanding the mechanisms that regulate the rate of beta-cell replication in human genetic disease and normal aging, we propose to identify therapeutic targets that will effectively increase the number of functional beta-cells, thus ameliorating diabetes. To this end, we will employ state-of-the-art and even emerging technologies to map the human epigenome, and to modify it in a targeted fashion to promote human beta-cell replication.